Skip to content
Back to explorer
Printable monograph

PI3Kδ inhibitor

Idelalisib

Zydelig · IDE

PI3Kδ inhibitor · approved 2014 · 6 citations · FAERS AKI reporting ROR 1.87 (95% CI 1.57–2.24, 124 AKI reports)

Aging evidence· through 2021
Fairly sourced5/9 · 5 signals
  • Met: 6 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 7y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Not met: Current through 2021
  • Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

First-in-class PI3K-delta inhibitor whose immune-mediated colitis and severe diarrhea can dehydrate patients into prerenal AKI.

MildFirst-generation B-cell PI3K inhibitor
Relapsed chronic lymphocytic leukemia (with rituximab)Relapsed follicular B-cell non-Hodgkin lymphoma and small lymphocytic lymphoma

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Extensively protein-bound and hepatically metabolized, not meaningfully dialyzable with no established ESKD dosing; monitor in CKD but dose changes are driven by colitis/hepatotoxicity/cytopenias.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: Zydelig, Sep 2026. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

Severe immune-mediated diarrhea/colitis occurs in roughly 14-20% (grade 3+) and transaminitis is common; secondary prerenal AKI from volume loss is not separately quantified. Direct renal lesions are rare.Source: Furman et al., N Engl J Med 2014 (PMID 24450857; registrational idelalisib + rituximab CLL trial); Lampson et al., Blood Adv 2019 (PMID 30967392; grade >=3 colitis/diarrhea 15%, first-line); Coutré et al., Leuk Lymphoma 2015 (PMID 25726955; expert-panel review of idelalisib diarrhea/colitis)

Onset & rechallenge

Time to injuryDelayed (>6 weeks / cumulative)

Diarrhea/colitis is often delayed to a median of several months into therapy, while transaminitis tends to appear earlier, in the first weeks. Prose gives no concrete day counts.

Distilled from: “Diarrhea/colitis often delayed — a median of several months into therapy; transaminitis is typically earlier (first weeks).”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

  2. Acute Interstitial NephritisSecondaryqualitative — no citable incidence

    Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.

§03

Kidney injury

Mechanism of kidney injury

PI3K-delta inhibition impairs regulatory T-cell function, producing a class-characteristic autoimmune-type inflammatory toxicity — colitis/enteritis, hepatitis and pneumonitis. The kidney is injured indirectly: profuse secretory diarrhea and reduced intake cause extracellular volume depletion and prerenal azotemia; severe sustained hypoperfusion can tip into ischemic ATN. Rare immune-mediated interstitial nephritis is biologically plausible within this autoimmune toxicity spectrum.

Clinical presentation

Watery, sometimes severe diarrhea (often after months of therapy), weight loss, orthostatic hypotension; creatinine rises with a low FeNa and concentrated urine. Concurrent transaminitis is a clue to the broader immune-toxicity syndrome.

Management

For severe diarrhea/colitis: interrupt idelalisib, exclude infection, rehydrate, and use systemic corticosteroids (e.g. budesonide or prednisone) for immune-mediated colitis. Restore volume to reverse prerenal AKI; if creatinine does not improve with euvolemia, consider AIN and a steroid trial. Permanently discontinue for life-threatening toxicity.Lesion-level management framework

Risk factors

  • Younger, treatment-naive patients (paradoxically higher autoimmune toxicity)
  • Pre-existing CKD or diuretic use
  • Concurrent nephrotoxins
  • Inadequate volume repletion during diarrhea

Prevention

  • Counsel on early reporting of diarrhea; rule out infection (including CMV) before attributing to drug
  • Aggressive oral/IV rehydration during diarrheal episodes
  • Prompt drug interruption for grade 3+ diarrhea/colitis
Anticancer mechanism· how it treats cancer

Oral selective inhibitor of the p110-delta isoform of PI3K, which is expressed predominantly in leukocytes. Blocking PI3K-delta disrupts B-cell receptor signaling and survival in chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma.

Note · Renal involvement is indirect — driven by immune-mediated colitis/diarrhea and volume depletion rather than a primary renal lesion; rare AIN is plausible within the autoimmune toxicity spectrum.
§04

Clinical depth

Renal dose adjustment

No specific renal dose adjustment is defined; metabolism is hepatic (CYP3A/aldehyde oxidase). Caution and monitor in CKD; dose changes are driven by colitis, hepatotoxicity and cytopenias.

Dialyzability & ESKD dosing

Extensively protein-bound; not meaningfully dialyzable. No established ESKD dosing.

Differential diagnosis

Distinguish prerenal AKI (low FeNa, responds to volume) from C. difficile or CMV colitis-driven losses, drug-induced AIN (pyuria, WBC casts) and hepatorenal physiology from concurrent hepatotoxicity.

Monitoring

  • LFTs every 2 weeks for the first 3 months, then periodically
  • Stool frequency and volume status; weight
  • Serum creatinine/electrolytes during diarrheal episodes
  • Infection surveillance (PJP prophylaxis; CMV monitoring)

Key trials & series

  • Furman et al. (NEJM 2014) — registrational idelalisib + rituximab CLL trial
  • Lampson et al. (Blood Adv 2019) — immune-mediated hepatotoxicity/colitis characterization

Clinical pearls

  • Idelalisib toxicity is autoimmune in flavor — colitis, hepatitis and pneumonitis cluster together.
  • Always exclude CMV/infectious colitis before steroids for presumed immune colitis.
  • The kidney injury is almost always volume-mediated; rehydration is the primary therapy.
  • Watch for PJP and CMV — boxed/serious infection warnings accompany this drug.
Where it strikes· nephron segments & injury signatures

Nephron segments

Vasculature / Endothelium

Glomerular & peritubular capillaries

Interstitium

Supporting tissue around the tubules

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2014–2021 · 2 since 2019
102014: 1 citation2015: 1 citation2017: 1 citation2018: 1 citation2019: 1 citation2021: 1 citation201420202021

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkIdelalisib and rituximab in relapsed chronic lymphocytic leukemia.Furman RR et al. · N Engl J Med · 2014 · PMID 24450857Registrational trial establishing efficacy and the diarrhea/colitis and transaminitis safety profile.
  2. 2.Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.Lampson BL et al. · Blood Adv · 2019 · PMID 30967392Phase 2 first-line idelalisib+ofatumumab trial documenting high-grade transaminitis (52%) and colitis/diarrhea (15%) severe enough to force early closure — the immune-mediated GI/hepatic toxicity that can precipitate volume depletion.
  3. 3.Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.Zelenetz AD et al. · Lancet Oncol · 2017 · PMID 28139405Phase 3 safety data including infection and GI toxicity informing risk-benefit.
  4. 4.Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.Pleyer C et al. · Leuk Lymphoma · 2018 · PMID 29764250Review of idelalisib's immune-related adverse effects (colitis, hepatotoxicity, pneumonitis, infections) arising from its immunomodulatory activity in CLL.
  5. 5.A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).Eyre TA et al. · Br J Haematol · 2021 · PMID 34121184Real-world toxicity and tolerability data outside trial conditions.
  6. 6.Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.Keating GM et al. · Target Oncol · 2015 · PMID 25637459Approval profile summarizing pharmacology and class safety.
FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION Fatal and/or serious hepatotoxicity occurred in 16% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig as recommended [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) ] . Fatal and/or serious and severe diarrhea or colitis occurred in 20% of Zydelig-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue Zydelig as recommended [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] . Fatal and/or serious pneumonitis occurred in 4% of Zydelig-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig as recommended [see Dosage and Administration (2.2) , Warnings and Precautions (5.3) ] . Fatal and/or serious infections occurred in 48% of Zydelig-treated patients. Monitor for signs and symptoms of infection. Interrupt Zydelig if infection is suspected [see Dosage and Administration (2.2) , Warnings and Precautions (5.4) ]. Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials. Discontinue Zydelig for intestinal perforation [see Warnings and Precautions (5.5) ] .…

Kidney rows of the label's dosage tables

From the Zydelig label (Sep 2026) · DailyMed

No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 7,144 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 1 signal

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
  • Acute Interstitial NephritisNot measurable in reporting — Reporters cannot reliably name this lesion, so its absence from FAERS is expected and is not evidence against the documented injury.
Electrolyte Disturbance
ROR 2.5395% CI 2.15–2.97· 149 reports· IC025 1.07
FAERS outcomes & reporting trend· 22.7% of reports w/ death · 43.1% w/ hospitalization
22.7%

Reported with a death outcome

1,622 of 7,144 reports

43.1%

Reported with hospitalization

3,081 of 7,144 reports

Reports per year

  • 2015: 1,439 reports
  • 2016: 1,377 reports
  • 2017: 1,232 reports
  • 2018: 987 reports
  • 2019: 596 reports
  • 2020: 399 reports
  • 2021: 257 reports
  • 2022: 197 reports
  • 2023: 182 reports
  • 2024: 113 reports
  • 2025: 94 reports
  • 2026: 10 reports

Reports received per year, 2015–2026 · most recent year is partial · 261 of the 7,144 reports predate 2015 and are not drawn.

FAERS adverse-event signal — all organ systems· 9 systems · 7,144 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 1.8795% CI 1.57–2.24· 124 AKI reports· IC025 0.62·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.
Renal & urinary
Acute Kidney Injury124
Gastrointestinal
Diarrhoea775Colitis203Nausea174Vomiting168
General / constitutional
Pyrexia386Fatigue304Asthenia203Weight Decreased177Malaise150
Immune / infection
Pneumonia439Sepsis163Infection150
Respiratory
Dyspnoea222Pneumonitis201Cough160
Blood & lymphatic
Neutropenia228Febrile Neutropenia154Anaemia116
Metabolic & electrolyte
Dehydration247Decreased Appetite147
Skin
Rash183
Cardiac
Atrial Fibrillation121
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Idelalisib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Duvelisib

Copiktra · PI3Kδ/γ inhibitor

Profile

Colitis and diarrhea → prerenal AKI.

PREAIN
Mild#1 · 100% phenotype match

Sacituzumab govitecan

Trodelvy · Antibody-drug conjugate (Trop-2/SN-38)

Profile

Diarrhea-driven prerenal AKI; emerging direct signals.

PREATNAIN
Moderate#2 · 54% phenotype match

Elotuzumab

Empliciti · Anti-SLAMF7 mAb

Profile

Kidney-neutral antibody; unchanged PK in severe impairment and dialysis; no renal dose adjustment.

PRE
Mild#3 · 53% phenotype match

Radium-223 dichloride

Xofigo · Radiopharmaceutical (alpha-emitter)

Profile

Bone-seeking alpha emitter; minimal direct renal toxicity.

PRE
Mild#4 · 53% phenotype match

Pexidartinib

Turalio · CSF1R inhibitor

Profile

Boxed hepatotoxicity; secondary renal effects.

PRE
Mild#5 · 53% phenotype match

Tisotumab vedotin

Tivdak · Antibody-drug conjugate (tissue factor/MMAE)

Profile

Ocular/bleeding toxicity dominates; renal involvement essentially unreported.

PRE
Mild#6 · 53% phenotype match
Compare Idelalisib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across PI3K / AKT inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1DuvelisibMild
  2. 1GedatolisibFAERS n/aMild
  3. 3Idelalisib· this agentFAERS AKIMild
  4. 4CopanlisibModerate
  5. 5AlpelisibModerate
  6. 6InavolisibFAERS AKIModerate
  7. 7CapivasertibFAERS AKIModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.